Erfolgsgeschichten
Var2 Pharma
Based on the groundbreaking discovery of a secondary carbohydrate modification omnipresent in the cancer matrisome and absent from normal tissues beside placenta, we have developed a portfolio of antibodies binding this onco-fetal modification. The antibodies have an unprecedented affinity and specificity for tumor tissues, holding the promise to be developed to treatments for cancers including malignancies where there is no effective therapy, such as sarcomas, triple negative breast cancers, glioblastomas, and prostate cancers.
VarCT Diagnostics
VarCT Diagnostics is engaged in the design and development of novel technology for capturing and analysis of circulating tumor cells of diverse origin, ultimately aiming for methods that will allow early screening and detection of all types of cancer
OncoOne
OncoOne is a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases. Our founders discovered the oxidized macrophage migration inhibitory factor (oxMIF), one of the most important drivers of innate and adaptive immunity.